Not available
Quote | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Last: | $1.46 |
---|---|
Change Percent: | -0.66% |
Open: | $1.53 |
Close: | $1.46 |
High: | $1.545 |
Low: | $1.4217 |
Volume: | 1,280,760 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
2024-04-19 13:49:43 ET Summary SELLAS Life Sciences Group, Inc. is a late-stage biotech company with a leading drug candidate, Galinpepimut-S, or GPS, that has a 44% probability of success and a potential 9x return. GPS is an immunotherapy drug targeting the Wilms Tumor 1 antigen,...
2024-03-28 16:57:07 ET More on SELLAS Life Sciences SELLAS Life Sciences looks to raise $20M in a direct offering Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment Seeking Alpha’s Quant Rating on SELLAS Life Sciences Hist...
Message Board Posts | SELLAS Life Sciences Group Inc. (NASDAQ:SLS)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $SLS News Article - Solaris Discovers New Porphyry Southwest of Warintza Central, with | whytestocks | investorshangout | 04/11/2023 4:30:58 PM |
After that dilution itl double in price, always does | harry crumb | investorshub | 03/03/2023 4:19:41 PM |
Breakout coming, this science could be a game changer | harry crumb | investorshub | 02/16/2023 2:23:43 AM |
Fingers crossed! Still an unknown, to us, | TTsr | investorshub | 02/03/2023 3:29:52 PM |
News coming? Its rippn | harry crumb | investorshub | 02/03/2023 3:17:11 PM |
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
Announced Phase 2a study of SLS009 in r/r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding the Targeted 20% and 100% Response Rate in Patients with Identified Biomarkers - Completed Enrollment in Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Scheduled in Late April -...